-$0.18 Earnings Per Share Expected for Cytosorbents Corp (CTSO) This Quarter
Wall Street brokerages expect Cytosorbents Corp (NASDAQ:CTSO) to post earnings of ($0.18) per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Cytosorbents’ earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.22). Cytosorbents reported earnings of ($0.10) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 80%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, May 14th.
On average, analysts expect that Cytosorbents will report full year earnings of ($0.65) per share for the current year, with EPS estimates ranging from ($0.89) to ($0.51). For the next year, analysts expect that the business will report earnings of ($0.31) per share, with EPS estimates ranging from ($0.59) to ($0.17). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Cytosorbents.
Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Thursday, March 7th. The medical research company reported ($0.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.04). The company had revenue of $6.08 million during the quarter, compared to analyst estimates of $6.08 million. Cytosorbents had a negative net margin of 76.48% and a negative return on equity of 94.30%.
CTSO stock traded down $0.12 during midday trading on Wednesday, reaching $7.04. The company had a trading volume of 80,588 shares, compared to its average volume of 111,857. The company has a market cap of $228.05 million, a PE ratio of -12.57 and a beta of 1.58. Cytosorbents has a 1-year low of $6.70 and a 1-year high of $14.95. The company has a quick ratio of 4.20, a current ratio of 4.32 and a debt-to-equity ratio of 0.55.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. raised its stake in Cytosorbents by 1.2% during the fourth quarter. BlackRock Inc. now owns 1,985,640 shares of the medical research company’s stock worth $16,046,000 after acquiring an additional 23,891 shares in the last quarter. Skylands Capital LLC raised its stake in Cytosorbents by 8.3% during the fourth quarter. Skylands Capital LLC now owns 495,850 shares of the medical research company’s stock worth $4,006,000 after acquiring an additional 37,800 shares in the last quarter. Allianz Asset Management GmbH raised its stake in Cytosorbents by 35.9% during the third quarter. Allianz Asset Management GmbH now owns 350,178 shares of the medical research company’s stock worth $4,517,000 after acquiring an additional 92,508 shares in the last quarter. Geode Capital Management LLC raised its stake in Cytosorbents by 5.9% during the fourth quarter. Geode Capital Management LLC now owns 301,498 shares of the medical research company’s stock worth $2,436,000 after acquiring an additional 16,679 shares in the last quarter. Finally, United Services Automobile Association raised its stake in Cytosorbents by 47.1% during the fourth quarter. United Services Automobile Association now owns 281,903 shares of the medical research company’s stock worth $2,278,000 after acquiring an additional 90,300 shares in the last quarter. 27.17% of the stock is owned by hedge funds and other institutional investors.
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.